Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730334 | 1.00 | CCR1 (0.80) | CCR1NR1I2 | |
| SCHEMBL1604365 | 1.00 | CCR1 (0.80) | CCR1NR1I2 | |
| SCHEMBL12708004 | 0.94 | CCR1 (0.80) | CCR1NR1I2 | |
| SCHEMBL1604345 | 0.93 | CCR1 (0.79) | CCR1NR1I2 | |
| SCHEMBL1604349 | 0.93 | CCR1 (0.79) | CCR1NR1I2 | |
| SCHEMBL12730341 | 0.93 | CCR1 (0.79) | CCR1NR1I2 | |
| SCHEMBL12707923 | 0.92 | CCR1 (0.78) | CCR1NR1I2 | |
| SCHEMBL12707995 | 0.92 | CCR1 (0.78) | CCR1NR1I2 | |
| SCHEMBL12730365 | 0.92 | CCR1 (0.78) | CCR1NR1I2 | |
| SCHEMBL12797592 | 0.92 | CCR1 (0.82) | CCR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178444-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-07-11 | — | — | US | disclosed |
| US-8410139-B2 | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178444-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR7, CCR1, CCR2 | CCR1 2/4885NR1I2 425/4885 |
| US-20110082113-A1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR7, CCR1, CCR2 | CCR1 2/4885NR1I2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.